Related Experiment Video
Updated: Jul 5, 2025
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
Evaluation of C-reactive protein and its prognostic relationship in patients with Hodgkin's Lymphoma
Elizete Negreiros1, Talita Máira Bueno da Silveira1, Sérgio Costa Fortier1
1Irmandade da Santa Casa de Misericórdia de São Paulo, Faculdade de Ciências Médicas da Santa Casa de São Paulo. São Paulo SP, Brazil.
Insights
C-Reactive Protein (CRP) levels at diagnosis and during treatment are important for monitoring Hodgkin´s Lymphoma patients. High CRP indicates advanced disease and predicts treatment response and survival.
Area of Science:
- Oncology
- Hematology
- Clinical Chemistry
Background:
- Hodgkin´s Lymphoma (HL) requires reliable prognostic markers.
- C-Reactive Protein (CRP) is an inflammatory marker with potential clinical utility in various cancers.
Purpose of the Study:
- To evaluate the prognostic significance of C-Reactive Protein (CRP) in Hodgkin´s Lymphoma.
- To correlate CRP levels with disease stage, B symptoms, and treatment response.
Main Methods:
- Retrospective analysis of 68 Hodgkin´s Lymphoma patient records (2012-2016).
- Assessment of baseline and follow-up C-Reactive Protein (CRP) levels.
- Correlation of CRP levels with clinical parameters and treatment outcomes.
Main Results:
- Elevated baseline CRP was linked to advanced stage (p=0.015) and B symptoms (p=0.02).
- Low CRP post-chemotherapy predicted complete response (p=0.04/0.03).
- Treatment-refractory patients had a higher risk of mortality (p=0.002).
Conclusions:
- C-Reactive Protein (CRP) is a valuable tool for monitoring Hodgkin´s Lymphoma.
- CRP levels correlate with disease severity and predict treatment outcomes.
- Persistent high CRP indicates refractoriness and poorer prognosis.
Objectives:
To assess the prognostic value of C-Reactive Protein (CRP), at diagnosis and during follow-up, of patients with Hodgkin´s Lymphoma treated at the Hematology Service of the Santa Casa de São Paulo Hospital, and to correlate serum CRP levels with disease stage and treatment response.
Methods:
A retrospective study involving review of 71 medical records of patients diagnosed with Hodgkin´s Lymphoma between February 2012 and January 2016 was performed. Three patients were subsequently excluded, giving a total of 68 patients for analysis. A level of CRP > 1 mg/dl was considered elevated.
Results:
Patients were predominantly male (61.8 %) and mean age was 34 years. Fifty-three (78 %) patients had advanced stage and (76.5 %) had B symptoms. Elevated baseline CRP was associated with greater likelihood of B symptoms (p = 0.02) and of advanced stage (p = 0.015). Patients with Low CRP level after 5th and 6th cycles of chemotherapy was associated with complete response (p = 0.04 and p = 0.03, respectively). Treatment-refractory patients had greater risk of death (p = 0.002).
Conclusion:
CRP is clinically important for follow-up of patients with Hodgkin´s Lymphoma, where high levels were associated with advanced disease and/or presence of B symptoms. CRP level was considered a predictor of treatment response. Persistence of high CRP values during treatment was associated with refractoriness.
More Related Videos
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
